UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 10-Q

(Mark One)

     [X]      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
              SECURITIES EXCHANGE ACT OF 1934

              For the quarterly period ended February 28, 2001.

 OR

     [ ]      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
              SECURITIES EXCHANGE ACT OF 1934

              For the transition period from _______________ to _______________.

Commission file Number 0-12515.

BIOMET, INC.
(Exact name of registrant as specified in its charter)

Indiana                                                      35-1418342
(State or other jurisdiction of                              (I.R.S. Employer
incorporation or organization)                               Identification No.)

56 East Bell Drive, Warsaw, Indiana  46582
(Address of principal executive offices)

(219) 267-6639
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.  Yes  X    No

As of February 28, 2001, the registrant had 178,943,519 common shares
outstanding.


BIOMET, INC.

CONTENTS

                                              										                 Pages

    Part I.  Financial Information

      Item 1.  Financial Statements:

                 Consolidated Balance Sheets                               1-2

                 Consolidated Statements of Income                           3

                 Consolidated Statements of Cash Flows                       4

                 Notes to Consolidated Financial Statements                5-7

      Item 2.  Management's Discussion and Analysis of
               Financial Condition and Results of Operations              8-10

      Item 3.  Quantitative and Qualitative Disclosure about
               Market Risks                                                 10

    Part II.   Other Information                                            11

    Signatures                                                              12

    Index to Exhibits                                                       13



PART I.  FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

BIOMET, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
at February 28, 2001 and May 31, 2000
(in thousands)

ASSETS
                                               February 28,        May 31,
                                                   2001             2000
                                               ------------        -------
                                                (Unaudited)
Current assets:
  Cash and cash equivalents                     $  203,173       $  213,606
  Investments                                       12,857           34,129
  Accounts and notes receivable, net               304,392          249,792
  Inventories                                      271,221          240,162
  Deferred income taxes                             32,801           25,811
  Prepaid expenses and other                        31,423           26,128
                                                 ---------        ---------
      Total current assets                         855,867          789,628
                                                 ---------        ---------
Property, plant and equipment, at cost             324,666          299,294
    Less, Accumulated depreciation                 137,566          116,037
                                                 ---------        ---------
      Property, plant and equipment, net           187,100          183,257
                                                 ---------        ---------
Investments                                        195,193          159,533
Intangible assets, net                              10,675            9,100
Excess acquisition costs over fair value
  of acquired net assets, net                      142,311           60,654
Other assets                                        16,961           16,276
                                                 ---------        ---------
Total assets                                    $1,408,107       $1,218,448
                                                 =========        =========

The accompanying notes are a part of the consolidated financial statements.

BIOMET, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
at February 28, 2001 and May 31, 2000
(in thousands)

LIABILITIES AND SHAREHOLDERS' EQUITY
                                                February 28,        May 31,
                                                    2001             2000
                                                ------------        -------
                                                 (Unaudited)
Current liabilities:
  Short-term borrowings                          $   71,967       $   70,546
  Accounts payable                                   20,916           25,612
  Accrued income taxes                               13,898           17,288
  Accrued wages and commissions                      29,730           24,224
  Other accrued expenses                             84,628           43,773
                                                  ---------        ---------
     Total current liabilities                      221,139          181,443

Long-term liabilities:
  Deferred federal income taxes                       7,409            5,386
  Other liabilities                                     425              423
                                                  ---------        ---------
     Total liabilities                              228,973          187,252
                                                  ---------        ---------
Minority interest                                    92,625           87,873
                                                  ---------        ---------

Contingencies (Note 8)

Shareholders' equity:
  Common shares                                     101,557           85,086
  Additional paid-in capital                         41,451           41,451
  Retained earnings                                 985,447          866,011
  Accumulated other comprehensive loss              (41,946)         (49,225)
                                                  ---------        ---------
     Total shareholders' equity                   1,086,509          943,323
                                                  ---------        ---------
Total liabilities and shareholders' equity       $1,408,107       $1,218,448
                                                  =========        =========

The accompanying notes are a part of the consolidated financial statements.


BIOMET, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME
for the nine and three month periods ended February 28, 2001
and February 29, 2000
(Unaudited, in thousands, except per share data)

                                    Nine Months Ended      Three Months Ended
                                    -----------------      ------------------
                                    2001        2000        2001        2000
                                    ----        ----        ----        ----

Net sales                         $739,992    $670,366    $266,276    $232,910

Cost of sales                      211,571     203,256      74,155      70,393
                                   -------     -------     -------     -------
  Gross profit                     528,421     467,110     192,121     162,517

Selling, general and
  administrative expenses          267,089     236,807      96,975      83,792
Research and development expense    31,533      29,534      11,374      10,959
Special charge                      26,100      11,700      26,100       2,700
                                   -------     -------     -------     -------
  Operating income                 203,699     189,069      57,672      65,066

Other income, net                   14,107      11,923       3,926       4,895
                                   -------     -------     -------     -------
  Income before income taxes
    and minority interest          217,806     200,992      61,598      69,961

Provision for income taxes          74,624      73,129      21,112      25,317
                                   -------     -------     -------     -------
  Income before minority interest  143,182     127,863      40,486      44,644

Minority interest                    4,752       4,713       2,281       1,452
                                   -------     -------     -------     -------
  Net income                      $138,430    $123,150    $ 38,205    $ 43,192
                                   =======     =======     =======     =======
Earnings per share:
  Basic                               $.78        $.70        $.21        $.24
                                      ====        ====        ====        ====
  Diluted                             $.77        $.69        $.21        $.24
                                      ====        ====        ====        ====
Shares used in the computation
  of earnings per share:
  Basic                            178,422     175,736     178,830     176,951
                                   =======     =======     =======     =======
  Diluted                          180,374     178,540     181,020     179,248
                                   =======     =======     =======     =======
Cash dividends per common share       $.11        $.09        $ --        $ --
                                      ====        ====        ====        ====

The accompanying notes are a part of the consolidated financial statements.

BIOMET, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
for the nine months ended February 28, 2001 and February 29, 2000
(Unaudited, in thousands)

                                                          2001          2000
                                                          ----          ----
Cash flows from (used in) operating activities:
  Net income                                            $138,430      $123,150
  Adjustments to reconcile net income to
    net cash from operating activities:
      Depreciation                                        22,704        20,306
      Amortization                                         9,094         6,467
      Gain on sale of investments, net                    (1,783)         (723)
      Minority interest                                    4,752         4,713
      Deferred federal income taxes                         (583)         (272)
      Changes in current assets and liabilities,
       excluding effects of acquisitions:
        Accounts and notes receivable, net               (29,348)      (24,194)
        Inventories                                      (26,704)      (25,459)
        Prepaid expenses and other                       (11,323)       (6,179)
        Accounts payable                                  (5,478)          674
        Accrued income taxes                              (5,943)       24,253
        Accrued wages and commissions                      4,179            61
        Other accrued expenses                            33,224       (58,660)
                                                         -------        ------
        Net cash from operating activities               131,221        64,137
                                                         -------        ------
Cash flows from (used in) investing activities:
  Proceeds from sales and maturities of investments       41,481        19,401
  Purchases of investments                               (54,177)      (28,608)
  Capital expenditures                                   (25,255)      (26,635)
  Acquisitions, net of cash acquired                     (90,602)      (18,142)
  Other                                                   (2,766)       (1,001)
                                                         -------        ------
        Net cash used in investing activities           (131,319)      (54,985)
                                                         -------        ------
Cash flows from (used in) financing activities:
  Increase (decrease) in short-term borrowings, net      (12,788)       24,980
  Issuance of common shares                               16,471         9,913
  Cash dividends                                         (18,993)      (16,468)
                                                         -------        ------
        Net cash from (used in) financing activities     (15,310)       18,425
                                                         -------        ------
Effect of exchange rate changes on cash                    4,975        (3,456)
                                                         -------        ------
Increase (decrease) in cash and cash equivalents         (10,433)       24,121
Cash and cash equivalents, beginning of year             213,606       132,081
                                                         -------       -------
Cash and cash equivalents, end of period                $203,173      $156,202
                                                         =======       =======

The accompanying notes are a part of the consolidated financial statements.

BIOMET, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1:     BASIS OF PRESENTATION.

The accompanying consolidated financial statements include the accounts of
Biomet, Inc. and its subsidiaries (individually and collectively referred to as
the "Company").  The unaudited consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for
interim financial information and with the instructions to Form 10-Q and Rule
10-01 of Regulation S-X.  Accordingly, they do not include all of the
information and notes required by generally accepted accounting principles for
complete financial statements.  In the opinion of management, all adjustments
(consisting of normal recurring accruals) considered necessary for a fair
presentation have been included.  Operating results for the nine-month period
ended February 28, 2001 are not necessarily indicative of the results that may
be expected for the fiscal year ending May 31, 2001.  For further information,
refer to the consolidated financial statements and notes thereto included in
the Company's Annual Report on Form 10-K for the fiscal year ended May 31, 2000.

The accompanying consolidated balance sheet at May 31, 2000, has been derived
from the audited Consolidated Financial Statements at that date, but does not
include all disclosures required by generally accepted accounting principles.

The Company has one reportable segment, musculoskeletal products, which includes
designing, manufacturing and marketing of reconstructive products, fixation
devices, spinal products and other products.  Other products consist primarily
of Arthrotek's arthroscopy products, AOA's softgood products, general
instruments and operating room supplies.  The Company manages its business
segment primarily on a geographic basis.  These geographic markets are comprised
of the United States, Europe and other.  Other geographic markets include
Canada, South America, Mexico, Japan and the Pacific Rim.

Net sales of musculoskeletal products by product category are as follows for the
nine and three months ended February 28, 2001 and February 29, 2000:

                                Nine Months Ended         Three Months Ended
                                -----------------         ------------------
                                2001        2000           2001        2000
                                ----        ----           ----        ----
                                               (in thousands)

     Reconstructive           $446,548    $422,738       $158,655    $146,828
     Fixation                  147,304     131,563         52,549      46,200
     Spinal products            62,230      38,571         26,429      13,452
     Other                      83,910      77,494         28,643      26,430
                               -------     -------        -------     -------
                              $739,992    $670,366       $266,276    $232,910
                               =======     =======        =======     =======

NOTE 2:     COMPREHENSIVE INCOME.

Other comprehensive income includes foreign currency translation adjustments
and unrealized appreciation of available-for-sale securities, net of taxes.
Other comprehensive income (loss) for the three months ended February 28, 2001
and February 29, 2000 was $21,280,000 and $(13,438,000), respectively.  Other
comprehensive income (loss) for the nine months ended February 28, 2001 and
February 29, 2000 was $7,279,000 and $(17,451,000), respectively.  Total
comprehensive income combines reported net income and other comprehensive
income.  Total comprehensive income for the three months ended February 28, 2001
and February 29, 2000 was $59,485,000 and $29,754,000, respectively. Total
comprehensive income for the nine months ended February 28, 2001 and February
29, 2000 was $145,709,000 and $105,699,000, respectively.

NOTE 3:     INVENTORIES.

Inventories at February 28, 2001 and May 31, 2000 are as  follows:

                               February 28,      May 31,
                                  2001            2000
                               ------------      -------
                                     (in thousands)

        Raw materials            $ 28,109       $ 28,511
        Work-in-process            31,641         28,962
        Finished goods            108,695        101,307
        Consigned inventory       102,776         81,382
                                  -------        -------
                                 $271,221       $240,162
                                  =======        =======

NOTE 4:     COMMON SHARES.

During the nine months ended February 28, 2001, the Company issued 1,290,292
Common Shares upon the exercise of outstanding stock options for proceeds
aggregating $16,471,000.  On July 6, 2000, the Company announced a three-for-two
stock split payable August 8, 2000 to shareholders of record July 18, 2000.  All
information on the number of common shares and all per share data for the
previous year have been restated for this stock split.

NOTE 5:     EARNINGS PER SHARE.

Earnings per common share amounts ("basic EPS") are computed by dividing net
income by the weighted average number of common shares outstanding and excludes
any potential dilution.  Earnings per common share amounts assuming dilution
("diluted EPS") are computed by reflecting potential dilution from the
exercise of stock options.

NOTE 6:     INCOME TAXES.

The difference between the reported provision for income taxes and a provision
computed by applying the federal statutory rate to pre-tax accounting income is
primarily attributable to state income taxes, tax benefits relating to
operations in Puerto Rico, tax-exempt income and tax credits.

NOTE 7:     ACQUISITIONS.

On September 25, 2000, the Company through its EBI subsidiary acquired
Biolectron, Inc. for $90 million in cash.  Biolectron's products principally
address the spinal fusion, fracture healing and arthroscopy market segments.
The Company accounted for this acquisition as a purchase.  Management has not
completed its final analysis of the allocation of the purchase price, but
anticipates that the average life expectancy of these intangibles will be
approximately 18 years.


NOTE 8:     CONTINGENCIES.

On January 18, 2001, the United States Court of Appeals for the Federal Circuit
(the "Federal Circuit") reinstated a $20 million punitive damages award against
the Company given to Raymond G. Tronzo by the United States District Court for
the Southern District of Florida (the "District Court") while affirming the
compensatory damage award of $520.  In its decision in this matter, the District
Court had reduced the punitive damage award to $52,000.  The Federal Circuit's
decision was based principally on procedural grounds, and concluded a finding
that a relationship of 38,000 to 1 between the punitive award and the
compensatory award was legally permissible.  On March 28, 2001, the Federal
Circuit denied the Company's combined petition for panel rehearing and petition
for rehearing en banc. The Company believes this result conflicts with
controlling law, including decisions of the United States Supreme Court.
Accordingly, the Company is seeking review of this case by the United States
Supreme Court.  It is important to note that this decision does not affect the
ongoing sales of any of Biomet's product lines. The Company has recorded a
one-time special charge during this quarter of $26.1 million in connection with
these damage awards which includes interest and related expenses.

There are various other claims, lawsuits, disputes with third parties,
investigations and pending actions involving various allegations against the
Company incident to the operation of its business, principally product liability
and intellectual property cases.  Each of these matters is subject to various
uncertainties, and it is possible that some of these matters may be resolved
unfavorably to the Company.  The Company establishes accruals for losses that
are deemed to be probable and subject to reasonable estimate.  Based on the
advice of counsel to the Company in these matters, management believes that the
ultimate outcome of these matters and any liabilities in excess of amounts
provided will not have a material adverse impact on the Company's consolidated
financial position or on its future business operations.

ITEM 2.     MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
            CONDITION AND RESULTS OF OPERATIONS

ACQUISITION

As discussed in Note 7 of the Notes to Consolidated Financial Statements, on
September 25, 2000, the Company acquired Biolectron, Inc. for $90 million in
cash.  The Company accounted for this acquisition as a purchase and the
operating results of Biolectron, Inc. have been consolidated from the date of
acquisition.

FINANCIAL CONDITION AS OF FEBRUARY 28, 2001

The Company's cash and investments increased $3,955,000 to $411,223,000 at
February 28, 2001, which includes the $18,993,000 cash dividend paid during the
first quarter and the $102,700,000 paid for acquisitions and debt payoff from
the acquired companies.

Cash flows provided by operating activities were $131,221,000 for the first nine
months of fiscal 2001 compared to $64,137,000 in 2000.  Net income plus
depreciation and amortization and an increase in other accrued expenses were
the principal sources of cash from operating activities, offset by increases in
accounts receivable, inventories and prepaid expenses and other assets.

Cash flows used in investing activities were $131,319,000 for the first nine
months of fiscal 2001 compared to a use of $54,985,000 in 2000.  The primary use
of cash flows for investing activities were purchases of investments, purchases
of capital equipment and business acquisitions offset by sales and maturities of
investments.

Cash flows used in financing activities were $15,310,000 for the first nine
months of fiscal 2001 compared to a source of $18,425,000 in 2000.  The primary
use of cash flows from financing activities was the cash dividend paid in the
first quarter and debt payoff from acquired companies while the primary source
of cash flows from financing activities was from cash receipts from stock option
exercises.

Currently available funds, together with anticipated cash flows generated from
future operations, are believed to be adequate to cover the Company's
anticipated cash requirements, including capital expenditures, research and
development costs and potential business acquisitions.

RESULTS OF OPERATIONS FOR THE NINE MONTHS ENDED FEBRUARY 28, 2001
AS COMPARED TO THE NINE MONTHS ENDED FEBRUARY 29, 2000

Net sales increased 10% to $739,992,000 for the nine-month period ended February
28, 2001, from $670,366,000 for the same period last year.   Excluding the
impact of foreign currency and discontinued products, which reduced the first
nine months sales by $26 million and $6.7 million, respectively, net sales
increased 15% during the first nine months of fiscal year 2001.  The
discontinued product line, which did not meaningfully contribute to the
Company's operating income, is associated with the Company's 3i division and its
June 1, 2000 termination of a distribution agreement with W. L. Gore &
Associates.  The product line represented regenerative and non-regenerative
membranes utilized in dental reconstructive procedures.  The Company's
U.S.-based revenue increased 16% to $518,191,000 during the first nine months,
while foreign sales decreased 1.2% to $221,801,000.  Excluding the negative
foreign exchange adjustment and discontinued products, domestic sales increased
17%, while foreign sales in local currencies increased 12%.  Biomet's worldwide
sales of reconstructive products during the first nine months of fiscal 2001
were $446,548,000, representing a 6% increase compared to the first nine months
of last year. This increase  was primarily a result of Biomet's continued
penetration of the reconstructive device market led by revision products, the
Repicci Unicondylar Knee, the Ascent Total Knee System and 3i's dental
reconstructive implants.  Sales of fixation products were $147,304,000 for the
first nine months of fiscal 2001, representing an 12% increase as compared to
the same period in 2000.  Sales of spinal products were $62,230,000 for the
first nine months of fiscal 2001, representing a 61% increase as compared to the
same period in 2000.  Sales of spinal hardware contributed to this increase.
Increases in both fixation and spinal products were positively influenced by the
acquisition of Biolectron in September of this fiscal year.  The Company's sales
of other products totaled $83,910,000, representing an 8% increase over the
first nine months of fiscal year 2000, primarily as a result of increased sales
of AOA's softgood products and Arthrotek's arthroscopy products.

Cost of sales decreased as a percentage of net sales to 28.6% for the first nine
months of fiscal 2001 from 30.3% last year primarily as a result of increased
sales of higher margin products, increased in-house manufacturing efficiencies
and improved margins realized through acquisitions of international
distributors.   Excluding the $26.1 million special charge for the Tronzo
litigation this quarter and the $11.7 million special charge for acquisition
related expenses and litigation matters during last year, selling, general and
administrative expenses as a percentage of net sales increased slightly from
35.3% for the first nine months of last year to 36.1% for the current nine
month period.  This increase in the percentage is a result of goodwill
amortization from the purchase of Biolectron, setting up direct distribution in
Japan and acquisitions of international distributors.  Research and development
expenditures increased during the first nine months to $31,533,000 reflecting
the Company's continued emphasis on new product introductions.  Operating income
increased 8% (14% excluding special charges) to $203,699,000 for the first nine
months of fiscal 2001.  Other income increased 18% resulting from the increase
in the Company's investable cash and higher investment yields.  The effective
income tax rate decreased to 34.3% for the first nine months of fiscal year 2001
from 36.4% last year primarily as a result of certain operating unit
realignments both in the United States and internationally and as a result of
U.S. pretax income growing at a higher rate than international pretax income
where tax rates are higher.

These factors resulted in a 12% increase in net income (19% excluding special
charges) to $138,430,000 for the first nine months of fiscal 2001 from
$123,150,000 as compared to the same period in fiscal 2000.  Basic earnings per
share increased 11% (18% excluding special charges), from  $.70 to $.78 for the
periods presented, while diluted earnings per share increased 12% (18% excluding
special charges), from  $.69 to $.77 for the periods presented.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED FEBRUARY 28, 2001
AS COMPARED TO THE THREE MONTHS ENDED FEBRUARY 29, 2000

Net sales increased 14% to $266,276,000 for the second quarter of fiscal 2001,
as compared to $232,910,000 for the same period last year.  Excluding the impact
of foreign currency and discontinued products, which reduced the second quarter
sales by $8 million and $2.3 million, respectively, net sales increased 19%
during the first nine months of fiscal year 2001.  Operating income decreased
11% (increased 24% excluding special charges) from $65,066,000 for the second
quarter of  fiscal 2000, to $57,672,000 for the second quarter of fiscal 2001.
During the second quarter, net income decreased 12% (increased 23% excluding
special charges) to $38,205,000 as compared to $43,192,000 for the same period
last year.  Basic and diluted earnings per share decreased 12% (increased 24%
excluding special charges), from  $.24 last year to $.21 this year for the
periods presented.  The business factors resulting in these changes and relevant
trends affecting the Company's business during the periods in question are
comparable to those described in the preceding discussion for the nine-month
period.

NEW ACCOUNTING STANDARDS

Staff Accounting Bulletin No 101, "Revenue Recognition in Financial Statements"
(SAB 101), provides guidance in applying generally accepted accounting
principles to selected revenue recognition issues in financial statements.  In
June 2000, the SEC issued SAB 101B, an amendment to SAB 101 which delays the
implementation of SAB 101 until no later than the fourth quarter of fiscal years
beginning after December 15, 1999.  This pronouncement is not expected to have a
material impact on the Company's financial position or results of operations.

Item 3.  Quantitative and Qualitative Disclosures about Market Risks.

There have been no material changes from the information provided in the
Company's Annual Report on Form 10-K for the year ended May 31, 2000.

PART II.  OTHER INFORMATION

Item 1: Legal Proceedings.

On January 18, 2001, the United States Court of Appeals for the Federal Circuit
(the "Federal Circuit") reinstated a $20 million punitive damages award against
the Company given to Raymond G. Tronzo by the United States District Court for
the Southern District of Florida (the "District Court") while affirming the
compensatory damage award of $520.  In its decision in this matter, the District
Court had reduced the punitive damage award to $52,000.  The Federal Circuit's
decision was based principally on procedural grounds, and concluded a finding
that a relationship of 38,000 to 1 between the punitive award and the
compensatory award was legally permissible.  On March 28, 2001, the Federal
Circuit denied the Company's combined petition for panel rehearing and petition
for rehearing en banc. The Company believes this result conflicts with
controlling law, including decisions of the United States Supreme Court.
Accordingly, the Company is seeking review of this case by the United States
Supreme Court.  It is important to note that this decision does not affect the
ongoing sales of any of Biomet's product lines. The Company has recorded a
one-time special charge during this quarter of $26.1 million in connection with
these damage awards which includes interest and related expenses.

Item 6.  Exhibits and Reports on Form 8-K

     (a)  Exhibits.  See Index to Exhibits.
     (b)  Reports on Form 8-K.
          None.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


BIOMET, INC.
------------
(Registrant)


DATE:  4/16/2001               BY: /s/  GREGORY D. HARTMAN
       ---------                   -------------------------
                                   Gregory D. Hartman
                                   Senior Vice President - Finance and Treasurer
                                   (Principal Financial Officer)

                                   (Signing on behalf of the Registrant
                                   and as Principal Financial Officer)

BIOMET, INC.

FORM 10-Q

INDEX TO EXHIBITS

                                                               Sequential
Number Assigned                                                Numbering System
in Regulation S-K                                              Page Number
Item 601               Description of Exhibit                  of Exhibit
-----------------      --------------------------------        ----------------
(2)                    No exhibit.

(4)                    4.1 Specimen certificate for Common
                       Shares.  (Incorporated by reference
                       to Exhibit 4.1 to the registrant's
                       Report on Form 10-K for the fiscal
                       year ended May 31, 1985).

                       4.2  Rights Agreement between Biomet,
                       Inc. and Lake City Bank, as Rights
                       Agent, dated as of December 2, 1989.
                       (Incorporated by reference to Exhibit
                       4 to Biomet, Inc. Form 8-K Current Report
                       dated December 22, 1989, File No. 0-12515).

(10)                   No exhibit.

(11)                   No exhibit.

(15)                   No exhibit.

(18)                   No exhibit.

(19)                   No exhibit.

(22)                   No exhibit.

(23)                   No exhibit.

(24)                   No exhibit.

(99)                   No exhibit.